Your browser doesn't support javascript.
loading
Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance.
Marin, Jose J G; Sanchon-Sanchez, Paula; Cives-Losada, Candela; Del Carmen, Sofía; González-Santiago, Jesús M; Monte, Maria J; Macias, Rocio I R.
Afiliación
  • Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Biomedical Research Institute (IBSAL), University of Salamanca, 37007 Salamanca, Spain.
  • Sanchon-Sanchez P; Centro de Investigación Biomédica en Red para el Estudio de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.
  • Cives-Losada C; Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Biomedical Research Institute (IBSAL), University of Salamanca, 37007 Salamanca, Spain.
  • Del Carmen S; Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Biomedical Research Institute (IBSAL), University of Salamanca, 37007 Salamanca, Spain.
  • González-Santiago JM; Department of Pathology, Biomedical Research Institute (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
  • Monte MJ; Department of Gastroenterology and Hepatology, Biomedical Research Institute (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain.
  • Macias RIR; Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Biomedical Research Institute (IBSAL), University of Salamanca, 37007 Salamanca, Spain.
Cancers (Basel) ; 13(10)2021 May 13.
Article en En | MEDLINE | ID: mdl-34068398

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: España
...